Baseline TNF‐α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease
Journal of Pediatric Gastroenterology and Nutrition · 17.11.2026
DOI: 10.1002/jpn3.70684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 17.11.2026. Verfasst von Yiyoung Kwon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Objectives
Crohn's disease (CD) is a systemic disorder in which conventional luminal endoscopic assessments may incompletely reflect overall inflammatory burden. We aimed to evaluate the associations between baseline inflammatory cytokines, disease phenotype, infliximab (IFX) pharmacokinetics, and the need for dose intensification (DI) in pediatric CD.
Methods
This prospective study included pediatric patients with moderate‐to‐severe CD treated with IFX. Tumor necrosis factor‐alpha (TNF‐α) and interleukin‐6 (IL‐6) levels were measured at diagnosis. Baseline imbalances were adjusted using propensity score matching and inverse probability of treatment weighting analyses.
Results
Of the 160 enrolled patients, 15 (9.4%) were not included in the 1‐year analysis, and 145 (90.6%) completed the 1‐year follow‐up. Body mass index (BMI)‐adjusted TNF‐α levels correlated with erythrocyte sedimentation rate ( R = 0.22, p = 0.008) and fecal calprotectin ( R = 0.34, p < 0.001), but not with simple endoscopic score for CD. In contrast, IL‐6 levels were not significantly associated with inflammatory biomarkers. Cytokine profiles and IFX trough levels were not associated with perianal disease status or disease location. DI was required in 94 of 145 patients (64.8%), and patients requiring DI demonstrated higher baseline TNF‐α levels than those without DI (49.63 ± 29.09 vs. 40.14 ± 16.59 pg/mL, p = 0.046).
Conclusions
Higher baseline TNF‐α levels were associated with subsequent IFX DI, while also correlating with conventional inflammatory biomarkers but not with SES‐CD or anatomical disease phenotype. These findings suggest that baseline TNF‐α may reflect an aspect of inflammatory burden relevant to subsequent treatment requirements that is not captured by luminal endoscopic severity or anatomical disease classification alone.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
ORCID-Profile: Yiyoung Kwon, Eun Sil Kim, Yoon Zi Kim, Tae Jong Jeong, Yon Ho Choe, Mi Jin Kim
Förderung
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Kwon, Y., Kim, E. S., Kim, Y. Z., Jeong, T. J., Choe, Y. H., & Kim, M. J. (2026). Baseline TNF‐α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70684
Vancouver
Kwon Y, Kim ES, Kim YZ, Jeong TJ, Choe YH, Kim MJ. Baseline TNF‐α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70684
BibTeX
@article{Kwon2026,
author = {Kwon, Yiyoung and Kim, Eun Sil and Kim, Yoon Zi and Jeong, Tae Jong and Choe, Yon Ho and Kim, Mi Jin},
title = {Baseline TNF‐α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70684}
}
EUVIMED